Rho激酶抑制剂对动脉瘤性蛛网膜下腔出血后迟发性脑血管痉挛的疗效研究  

Study on Rho-kinase inhibitor therapy for delayed cerebral vasospasm following aneurysmal subarachnoid hemorrhage

作　　者：封硕[1] 李爱民[2] 刘希光[2] 李宁[2] 

机构地区：[1]徐州医学院附属连云港医院神经外科,222002 [2]徐州医学院附属连云港第一人民医院神经外科

出　　处：《临床神经外科杂志》2011年第3期122-123,共2页Journal of Clinical Neurosurgery

摘　　要：目的探讨Rho激酶抑制剂对动脉瘤性蛛网膜下腔出血(aSAH)后迟发性脑血管痉挛(DCVS)的治疗效果。方法按照是否应用Rho激酶抑制剂对35例自发性性蛛网膜下腔出血后发生迟发性脑血管痉挛的患者资料和治疗效果进行回顾性分析。结果 Rho激酶抑制剂对迟发性脑血管痉挛临床症状改善率81.25%,与常规治疗组47.37%相比,具有统计学差异(P<0.05);治疗后,Rho激酶抑制组脑血流速度低于对照组(P<0.05)。结论 Rho激酶抑制剂能明显缓解aSAH后迟发性脑血管痉挛的临床症状,为神经外科防治迟发性脑血管痉挛提供了临床依据。Objective To explore the therapeutic effects of Rho-kinase inhibitor in treatment of delayed cerebral vasospasm （DCVS）following aneurysmal subarachnoid hemorrhage （aSAH）. Methods The clinical data of 35 patients with DCVS following aSAH by Rho-kinase inhibitor were analyzed retrospectively. Results The response rate in control group and Rho-kinase inhibitor therapy group were 47.37 % and 81.25 % which with the significant difference （ P 〈 0.05 ）. The flow velocity of middle cerebral artery （MCA） was significantly lower in Rho-kinase inhibitor therapy group than in control group （ P 〈 0.05 ）. Conclusion Rho-kinase inhibitor has a good effect on the therapeutic of DCVS following aSAH for the control of DCVS.

关 键 词：蛛网膜下腔出血 迟发性脑血管痉挛 RHO激酶抑制剂 

分 类 号：R743.35[医药卫生—神经病学与精神病学]